Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The free fatty acid receptors FFA2 and FFA3 are recently de‐orphanized G protein‐coupled receptors that share a group of short‐chain free fatty acids as endogenous ligands. The expression of FFA2 and FFA3 by immune cells, in parts of the gastro‐intestinal tract and by white adipocytes has suggested their potential as therapeutic targets in conditions including inflammation and obesity. However, although FFA2 and FFA3 display distinct structure–activity relationships for stimulation by short‐chain free fatty acids, the overlap between these endogenous agonists and the lack of synthetic small molecule ligands that display selectivity between these two receptors has, until recently, hindered efforts to resolve their individual functions. Recently, chloro‐α‐(1‐methylethyl)‐N‐2‐thiazolylbenzeneacetamide has been described as an FFA2 selective ago‐allosteric ligand, not only being a direct agonist but also acting as a positive allosteric modulator of the function of short‐chain free fatty acids at FFA2. Mutation of a pair of key arginine residues near the top of transmembrane domains V and VII of both FFA2 and FFA3 eliminates the function of short‐chain free fatty acids but is without effect on the direct agonist action of chloro‐α‐(1‐methylethyl)‐N‐2‐thiazolylbenzeneacetamide at FFA2, confirming the distinct nature of the binding site of the ago‐allosteric regulator from the orthosteric binding site for free fatty acids. An understanding of structure–activity relationships for ligands related to chloro‐α‐(1‐methylethyl)‐N‐2‐thiazolylbenzeneacetamide is likely to provide greater insight into the mode of action and site of binding of this ligand, but further FFA2 and FFA3 selective ligands, preferably with higher potency/affinity, will be required to fully explore the physiological function of these receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409
Le Poul, E., Loison, C., Struyf, S., Springael, J.-Y., Lannoy, V., Decobecq, M.-E., Brezillon, S., Dupriez, V., Vassart, G., Van Damme, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301403200 · Cited by 1,651
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538 · cited 3×
“…as well as the group of related GPCRs named free fatty acid receptors FFA1, FFA2 and FFA3 (previously designated GPR40, GPR43 and GPR41 respectively) (Briscoe et al., 2003; Brown et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003; Le Poul et al., 2003; see Stoddart et al., 2008a for review).”
BackgroundResultCitric acid cycle intermediates as ligands for orphan G-protein-coupled receptors
He, W., Miao, F. J.-P., Lin, D. C.-H., Schwandner, R. T., Wang, Z., Gao, J., Chen, J.-L., Tian, H., & Ling, L. (2004) · Nature · doi:10.1038/nature02488 · Cited by 909 · cited 3×
“2): S1–S209 and available at http://www.iuphar-db.org/ index.jsp Received 1 May 2009; revised 18 June 2009; accepted 29 June 2009 British Journal of Pharmacology (2009), 158, 146–153 © 2009 The Authors Journal compilation © 2009 The British Pharmacological Society All rights reserved 0007-1188/09 www.brjpharmacol.org…”
BackgroundThangaraju, M., Cresci, G. A., Liu, K., Ananth, S., Gnanaprakasam, J. P., Browning, D. D., Mellinger, J. D., Smith, S. B., Digby, G. J., Lambert, N. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4466 · Cited by 789 · cited 2×
“, 2005) [and/or butyrate (Thangaraju et al., 2009)] as an activator of GPR109A, aromatic D-amino acids as chemoattractant factors activating Correspondence: Graeme Milligan, Molecular Pharmacology Group, Neuroscience and Molecular Pharmacology, Faculty of Biomedical and Life Sciences, University of Glasgow, Glasgow G1…”
BackgroundLiu, C., Wu, J., Zhu, J., Kuei, C., Yu, J., Shelton, J., Sutton, S. W., Li, X., Yun, S. J., Mirzadegan, T., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806409200 · Cited by 606 · cited 2×
“2): S1–S209 and available at http://www.iuphar-db.org/ index.jsp Received 1 May 2009; revised 18 June 2009; accepted 29 June 2009 British Journal of Pharmacology (2009), 158, 146–153 © 2009 The Authors Journal compilation © 2009 The British Pharmacological Society All rights reserved 0007-1188/09 www.brjpharmacol.org…”
BackgroundNilsson, N. E., Kotarsky, K., Owman, C., & Olde, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00488-1 · Cited by 540
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs
Kotarsky, K., Nilsson, N. E., Flodgren, E., Owman, C., & Olde, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03064-4 · Cited by 352 · cited 1×
“…as well as the group of related GPCRs named free fatty acid receptors FFA1, FFA2 and FFA3 (previously designated GPR40, GPR43 and GPR41 respectively) (Briscoe et al., 2003; Brown et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003; Le Poul et al., 2003; see Stoddart et al., 2008a for review).”
BackgroundSalehi, A., Flodgren, E., Nilsson, N. E., Jimenez-Feltstrom, J., Miyazaki, J., Owman, C., & Olde, B. (2005) · Cell and Tissue Research · doi:10.1007/s00441-005-0017-z · Cited by 150
Cited by
Minireview: Gut microbiota: The neglected endocrine organ
Clarke, G., Stilling, R. M., Kennedy, P. J., Stanton, C., Cryan, J. F., & Dinan, T. G. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1108 · Cited by 1,192
He, J., Zhang, P., Shen, L., Niu, L., Tan, Y., Chen, L., Zhao, Y., Bai, L., Hao, X., Li, X., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176356 · Cited by 1,064
Nogal, A., Valdes, A. M., & Menni, C. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1897212 · Cited by 917
Short-chain fatty acids in diseases
Zhang, D., Jian, Y.-P., Zhang, Y.-N., Li, Y., Gu, L.-T., Sun, H.-H., Liu, M.-D., Zhou, H.-L., Wang, Y.-S., & Xu, Z.-X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01219-9 · Cited by 718
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Metadata
- Authors
- Milligan, G., Stoddart, L. A., & Smith, N. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2009-08-25
- Volume
- 158
- Issue
- 1
- Pages
- 146-153
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1998253541
- Cited by
- 68
- References
- 9
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. https://app.cochat.ai/papers/10.1111/j.1476-5381.2009.00421.x
- The paper
- Milligan, G., Stoddart, L. A., & Smith, N. J. (2009). Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2009.00421.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.